mofezolac has been researched along with Cancer of Intestines in 2 studies
mofezolac: Cyclooxygenase 1 inhibitor; structure in first source; RN from Toxlit
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kitamura, T | 2 |
| Kawamori, T | 1 |
| Uchiya, N | 1 |
| Itoh, M | 2 |
| Noda, T | 2 |
| Matsuura, M | 2 |
| Sugimura, T | 1 |
| Wakabayashi, K | 2 |
2 other studies available for mofezolac and Cancer of Intestines
| Article | Year |
|---|---|
Inhibitory effects of mofezolac, a cyclooxygenase-1 selective inhibitor, on intestinal carcinogenesis.
Topics: Animals; Antineoplastic Agents; Azoxymethane; Carcinogenicity Tests; Cyclooxygenase 1; Cyclooxygenas | 2002 |
Combined effects of cyclooxygenase-1 and cyclooxygenase-2 selective inhibitors on intestinal tumorigenesis in adenomatous polyposis coli gene knockout mice.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cyclooxygenase 1; Cyclooxygenase 2; Cycloox | 2004 |